MedTrace Logo

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

NCT02472392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-05-09

No results posted yet for this study

Summary

The purpose of this study is to examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory ES and rhabdomyosarcoma. This is a nanrandomized two-arm study is designed to determine the safety and incidence of graft versus host disease (GVHD) in patients with relapsed, refractory Ewings sarcoma receiving related and unrelated, allogeneic stem cell transplants.

Conditions

  • EWINGS SARCOMA

Interventions

DRUG

Rabbit anti-thymocyte globulin

Active treatment

DRUG

Busulfan

comparitor

DRUG

Melphalan

comparitor

DRUG

Fludarabine

comparitor

DRUG

Cyclophosphamide

comparitor

Sponsors & Collaborators

  • University of Louisville

    lead OTHER

Principal Investigators

  • Kenneth Lucas, M.D. · University of Louisville

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02472392 on ClinicalTrials.gov